It Is Clear Who Should Take Provenge And Who Should Not

Provenge, despite its demonstrated survival advantage continues to be knocked as a viable treatment for men with castrate resistant prostate cancer. Why is this the case? First,  Provenge does not affect the PSA. Most men will continue to see their PSA rise, as well as their disease progress based on scans, while they take the treatment. Remember, the total treatment time is one month long. Many of our other treatments do affect the PSA, so many men believe that Provenge is nothing more than a placebo. However, I have been saying that not all men are in fact candidates for [...]

We Need to Report Serious Adverse Events or Serious Drug Side Effects to the FDA – How You Can Make a Report

The Food and Drug Administration (FDA) is charged with protecting the general health and well being of Americans with medicines and certain treatment equipment. Sometimes these medications or treatment equipment fail, don't work as indicated or cause serious, life threatening side effects. Reporting these events is important so the FDA can track and monitor these issues allowing them to further evaluate the safety and efficacy of a product. The Food and Drug Administration's (FDA) has a program called MedWatch which is designed to report: 1- Serious Reactions 2- Product Quality Problems 3- Therapeutic Failure 4- Product Use Errors 5- Human [...]

CTCs As A Biomarker to Predict Survival in Men with Metastatic CRPC – Can We Be Triaged to Death?

Higher circulating tumor cell counts are associated with an increased risk of death. Men with metastatic castrate resistant prostate cancer don’t have a good biomarker to predict survival.  According to a study published online ahead of print in the Journal of Clinical Oncology. by Amir Goldkorn, MD, and colleagues at the Keck School of Medicine of the University of Southern California in Los Angeles,Measuring circulating tumor cells (CTCs) may be a more effective method of predicting survival compared with PSA tests. The researchers evaluated blood samples of 263 men with metastatic CRPC prior to their beginning chemotherapy. They enumerated CTCs at [...]